BioMarin Pharmaceutical Revenue 2006-2021 | BMRN

BioMarin Pharmaceutical annual/quarterly revenue history and growth rate from 2006 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • BioMarin Pharmaceutical revenue for the quarter ending June 30, 2021 was $0.502B, a 16.81% increase year-over-year.
  • BioMarin Pharmaceutical revenue for the twelve months ending June 30, 2021 was $1.917B, a 3.76% increase year-over-year.
  • BioMarin Pharmaceutical annual revenue for 2020 was $1.86B, a 9.18% increase from 2019.
  • BioMarin Pharmaceutical annual revenue for 2019 was $1.704B, a 14.27% increase from 2018.
  • BioMarin Pharmaceutical annual revenue for 2018 was $1.491B, a 13.52% increase from 2017.
BioMarin Pharmaceutical Annual Revenue
(Millions of US $)
2020 $1,860
2019 $1,704
2018 $1,491
2017 $1,314
2016 $1,117
2015 $890
2014 $749
2013 $548
2012 $501
2011 $441
2010 $376
2009 $325
2008 $296
2007 $122
2006 $84
2005 $26
BioMarin Pharmaceutical Quarterly Revenue
(Millions of US $)
2021-06-30 $502
2021-03-31 $486
2020-12-31 $452
2020-09-30 $477
2020-06-30 $429
2020-03-31 $502
2019-12-31 $454
2019-09-30 $461
2019-06-30 $388
2019-03-31 $401
2018-12-31 $353
2018-09-30 $392
2018-06-30 $373
2018-03-31 $373
2017-12-31 $358
2017-09-30 $334
2017-06-30 $317
2017-03-31 $304
2016-12-31 $300
2016-09-30 $280
2016-06-30 $300
2016-03-31 $237
2015-12-31 $228
2015-09-30 $209
2015-06-30 $250
2015-03-31 $203
2014-12-31 $229
2014-09-30 $177
2014-06-30 $192
2014-03-31 $152
2013-12-31 $147
2013-09-30 $137
2013-06-30 $137
2013-03-31 $128
2012-12-31 $132
2012-09-30 $128
2012-06-30 $124
2012-03-31 $117
2011-12-31 $108
2011-09-30 $113
2011-06-30 $111
2011-03-31 $109
2010-12-31 $102
2010-09-30 $98
2010-06-30 $92
2010-03-31 $85
2009-12-31 $87
2009-09-30 $81
2009-06-30 $83
2009-03-31 $74
2008-12-31 $99
2008-09-30 $73
2008-06-30 $64
2008-03-31 $60
2007-12-31 $45
2007-09-30 $25
2007-06-30 $29
2007-03-31 $23
2006-12-31 $6
2006-09-30 $25
2006-06-30 $23
2006-03-31 $14
2005-12-31 $1
2005-09-30 $8
2005-06-30 $4
2005-03-31 $5
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $13.594B $1.860B
BioMarin Pharmaceutical Inc. is a developer of carbohydrate enzyme therapies for debilitating, life-threatening, chronic genetic disorders and other diseases and conditions. The company completed a six-month evaluation of patients being treated with BioMarin's lead product, BM101, for the treatment of mucopolysaccharidosis-I, or MPS-I. Patients were treated with BM101 as part of a pivotal clinical trial completed to determine the safety and efficacy of the drug in humans.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.972B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $11.985B 20.30
Biohaven Pharmaceutical Holding (BHVN) United States $8.378B 0.00
Emergent Biosolutions (EBS) United States $2.740B 6.61
Arcus Biosciences (RCUS) United States $2.509B 0.00
Myovant Sciences (MYOV) United Kingdom $1.869B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.763B 0.00
Zymeworks (ZYME) Canada $1.061B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.333B 0.00
Enzo Biochem (ENZ) United States $0.157B 15.43